The Latest Class for Diabetes - 8 News NOW

Paula Francis, Anchor

The Latest Class for Diabetes

Posted: Updated:

FDA approval is still pending for a new diabetes drug called Galvus that's supposed to help the body balance sugar and insulin production. If approved, it will be the second in a new class of drugs -- with the first being Januvia -- approved in the U.S. last October. In this week's 'Dealing with Diabetes' segment, we take a closer look at what sets the new class apart from the rest.

The drug Januvia prevents the breakdown of GLP-1, a hormone that raises insulin production. It also indirectly inhibits the increase of blood-sugar levels. The once-a-day tablet is the first in a new class of drugs -- called DPP-4 inhibitors. Las Vegas endocrinologist, Fred Toffel, says it's especially ideal for treating an early onset of diabetes.

Dr. Toffel says, "Where it's best useful is early in the disease, people who are close to goal, where you just want to get them a bit lower and get lower safely. That's really where I see this niche. And that's a big niche."

With DPP-4 inhibitors, if blood sugar levels are normal, it doesn't do anything at all -- thereby reducing the risk of hypoglycemia or low sugar. Dr. Toffel says it's a safe drug that can be used alone or in combination. But unlike its well-known injectable counterpart, Byetta, Januvia does not appear to promote weight loss.

Dr. Toffel says, "It's not going to help you loose weight, but it's not going to have you gain weight. Also, essentially, very little side-effects."

Newer drugs are often more expensive and this is the case with Januvia. So depending on your coverage, it may or may not be affordable.

Dr. Toffel says,"The most cost-effective medicine for people are medically poor or have type-2 diabetes is diet and exercise. You get that for nothing. And it's by far still the number one treatment for type-2 disease."

Januvia is made by Merck Pharmaceuticals. It's expected to be a major boost for the drug company, after having to scrap their popular osteoarthritis drug, Vioxx.

Email your comments to Reporter Paula Francis.

  • Paula's Health NotesLas Vegas Health NewsMore>>

  • New procedure to help Lipedema

    New procedure to help Lipedema

    Friday, August 22 2014 3:55 PM EDT2014-08-22 19:55:58 GMT
    Some women just can't lose weight and for the estimated 11 percent of women with a chronic disorder, diet and exercise won't help at all. Now, there is a new procedure doctors are now using that can help restore their appearance.More>>
    Some women just can't lose weight and for the estimated 11 percent of women with a chronic disorder, diet and exercise won't help at all. Now, there is a new procedure doctors are now using that can help restore their appearance.More>>
  • Fixing gerd for good

    Fixing gerd for good

    Tuesday, August 19 2014 3:21 PM EDT2014-08-19 19:21:39 GMT
    Acid reflux disease, a condition commonly known as “GERD”, affects about one-third of Americans. It can cause pain, coughing, heartburn and can even lead to cancer. Now, a simple procedure may fix GERD for good.More>>
    Acid reflux disease, a condition commonly known as “GERD”, affects about one-third of Americans. It can cause pain, coughing, heartburn and can even lead to cancer. Now, a simple procedure may fix GERD for good.More>>
  • Ice cold heart therapy

    Ice cold heart therapy

    Friday, August 15 2014 5:05 PM EDT2014-08-15 21:05:13 GMT
    A trial fibrillation affects about 2.7 million Americans. It's a condition that causes heart palpitations, shortness of breath and dizziness. If left untreated, it can be life-threatening. Now doctors are freezing the problem away.More>>
    A trial fibrillation affects about 2.7 million Americans. It's a condition that causes heart palpitations, shortness of breath and dizziness. If left untreated, it can be life-threatening. Now doctors are freezing the problem away.More>>
Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KLAS. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.